SCHEMBL4242300

SCHEMBL4242300

NC(=O)CC[C@H](N)C(=O)Nc1ccc(N)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 7/20 0.48
MAPT P10636 1/20 0.47
RAB9A P51151 1/20 0.47
S1PR1 P21453 3/20 0.46
S1PR3 Q99500 3/20 0.46
SPHK1 Q9NYA1 4/20 0.44
SPHK2 Q9NRA0 1/20 0.44
KMT2A Q03164 3/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
PKM P14618 1/20 0.43
APEX1 P27695 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
ALOX15 P16050 1/20 0.43
BLM P54132 1/20 0.43
PMP22 Q01453 1/20 0.43
DPP4 P27487 1/20 0.43
DPP8 Q6V1X1 1/20 0.43
DPP9 Q86TI2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22085186 0.87 LTA4H (0.51) LTA4HMAPTS1PR1S1PR3SPHK1
SCHEMBL4242289 0.87 LTA4H (0.61) LTA4HMAPTRAB9AS1PR1S1PR3
SCHEMBL6286723 0.86 LTA4H (0.47) LTA4HS1PR1S1PR3SPHK1SPHK2
SCHEMBL11038424 0.84 LTA4H (0.49) LTA4HS1PR1S1PR3SPHK1SPHK2
SCHEMBL19234507 0.83 SPHK1 (0.53) LTA4HRAB9AS1PR1S1PR3SPHK1
SCHEMBL10884809 0.82 S1PR1 (0.54) LTA4HRAB9AS1PR1S1PR3KMT2A
SCHEMBL24324831 0.81 SPHK1 (0.61) S1PR1S1PR3SPHK1SPHK2S1PR2
SCHEMBL20715888 0.81 GAA (0.56) LTA4HMAPTS1PR1S1PR3SPHK1
SCHEMBL20238865 0.81 LTA4H (0.67) LTA4HS1PR1S1PR3SPHK1SPHK2
SCHEMBL7132441 0.81 LTA4H (0.55) LTA4HS1PR1S1PR3SPHK1SPHK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315973-A1 PARP-1 INHIBITORS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2014-10-23 US disclosed
WO-2013052006-A1 PARP-1 INHIBITORS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) 2013-04-11 WO disclosed
US-7481781-B2 Ultrasound therapy GENDEL LIMITED (GB) 2009-01-27 US disclosed
EP-1506039-B1 ABLATION DEVICE GENDEL LTD (GB) 2008-10-29 EP disclosed
WO-2006044716-A2 CELL PERMEABLE NANOCONJUGATES OF SHELL-CROSSLINKED KNEDEL (SCK) AND PEPTIDE NUCLEIC ACIDS ('PNAs') WITH UNIQUELY EXPRESSED OR OVER-EXPRESSED mRNA TARGETING SEQUENCES FOR EARLY DIAGNOSIS AND THERAPY OF CANCER WASHINGTON UNIVERSITY IN ST.LOUIS (US) 2006-04-27 WO disclosed
EP-1196143-B1 USE OF AN ELECTRIC FIELD FOR SENSITISING RED BLOOD CELLS TO ULTRASOUND UUTECH LTD (GB) 2006-03-01 EP disclosed
US-20050043726-A1 Device II GENDEL LIMITED (GB) 2005-02-24 US disclosed
US-6821274-B2 DISRUPTING DISEASED AREA WHILE MINIMIZING HARM TO NEIGHBORING HEALTHY CELLS; PRETREATMENT WITH ELECTRIC FIELD GENDEL LTD. (IE) 2004-11-23 US disclosed
US-6812204-B1 ELECTROSENSITIZING RED BLOOD CELL; APPLYING SOUND WAVES GENDEL LIMITED (GB) 2004-11-02 US disclosed
WO-2004083391-A2 TARGETED AND REGIONAL CELLULAR ABLATION IN ZEBRAFISH WASHINGTON UNIVERSITY IN ST. LOUIS (US) 2004-09-30 WO disclosed
EP-1253912-A1 APPARATUS FOR PROVIDING A RED BLOOD CELL CARRIER Gendel Limited (GB) 2002-11-06 EP disclosed
US-20020151004-A1 Delivery vehicles and methods for using the same CRAIG ROGER (GB) 2002-10-17 US disclosed
WO-2002007752-A2 RED BLOOD CELL AS VEHICLE FOR AGENT-MEMBRANE TRANSLOCATION SEQUENCE CONJUGATE GENDEL LIMITED (GB) 2002-01-31 WO disclosed
US-20020009706-A1 Method for loading cells with an agent MCHALE ANTHONY P (IE) 2002-01-24 US disclosed
US-20010053549-A1 Loading method GENDEL LIMITED (GB) 2001-12-20 US disclosed
US-20010031499-A1 Loading system and method for using the same GENDEL LIMITED (GB) 2001-10-18 US disclosed
WO-2001058432-A1 APPARATUS FOR PROVIDING A RED BLOOD CELL CARRIER GENDEL LIMITED (GB) 2001-08-16 WO disclosed
US-20010008758-A1 Delivery of an agent UUTECH LIMITED (GB) 2001-07-19 US disclosed
EP-0970232-A2 NON-IMMUNOGENIC PRODRUGS AND SELECTABLE MARKERS FOR USE IN GENE THERAPY Chiron Corporation (US) 2000-01-12 EP disclosed
WO-1998030709-A2 NON-IMMUNOGENIC PRODRUGS AND SELECTABLE MARKERS FOR USE IN GENE THERAPY CHIRON CORPORATION (US) 1998-07-16 WO disclosed